BMDMs were treated for 3 h with PAR-1 agonist peptide/TFLLR (10 μM) alone or simultaneously with enzymatically-active tPA (EA-tPA) or EI-tPA (12 or 24 nM). Separate cultures were treated with RLLFT (10 μM) as a negative control peptide. Expression of the mRNAs encoding TNFα, IL-1β, IL-6 and CCL2 was determined (mean ± SEM; n = 4; **p<0.01, ***p<0.001, N.S., not statistically significant; one-way ANOVA with Bonferroni’s post hoc test). The presented results show “fold increase” in mRNA expression compared with cultures treated with vehicle.